With preclinical data demonstrating the functional involvement of ABCG2 in resistance to several anti-cancer drugs, studies should now be undertaken to clinically investigate ABCG2 as a predictive biomarker, including validation of the proposed scoring protocol. This evidence concerns the gene ABCG2 and cancer.